These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 20102913

  • 1. Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
    Lee SW, Chun KJ, Park SW, Kim HS, Kim YH, Yun SC, Kim WJ, Lee JY, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Jon S, Cho YH, Lee NH, Kim JH, Park SJ.
    Am J Cardiol; 2010 Jan 15; 105(2):168-73. PubMed ID: 20102913
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.
    Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Park SJ, Lee JH, Choi SW, Seong IW, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Choi YJ, Kim HS, Lee BK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Park WJ, DECLARE-LONG II Study Investigators.
    J Am Coll Cardiol; 2011 Mar 15; 57(11):1264-70. PubMed ID: 21392640
    [Abstract] [Full Text] [Related]

  • 3. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients).
    Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ.
    J Am Coll Cardiol; 2008 Mar 25; 51(12):1181-7. PubMed ID: 18355656
    [Abstract] [Full Text] [Related]

  • 4. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
    Lee SW, Park SW, Yun SC, Kim YH, Park DW, Kim WJ, Lee JY, Lee CW, Hong MK, Kim JJ, Park SJ.
    Am Heart J; 2010 Feb 25; 159(2):284-291.e1. PubMed ID: 20152228
    [Abstract] [Full Text] [Related]

  • 5. Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
    Lee SW, Lee JY, Ahn JM, Park DW, Han S, Park YK, Lee WS, Jang JY, Kwon CH, Park GM, Cho YR, Kim WJ, Kang SJ, Kim YH, Lee CW, Kim JJ, Park SW, Park SJ.
    Am J Cardiol; 2013 Dec 01; 112(11):1738-44. PubMed ID: 24063835
    [Abstract] [Full Text] [Related]

  • 6. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
    Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS.
    J Am Coll Cardiol; 2011 Jan 18; 57(3):280-9. PubMed ID: 21232664
    [Abstract] [Full Text] [Related]

  • 7. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS.
    Circulation; 2012 Jan 24; 125(3):505-13. PubMed ID: 22179532
    [Abstract] [Full Text] [Related]

  • 8. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW, Kang SH, Park JJ, Yang HM, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Chae IH, Kim HS.
    JACC Cardiovasc Interv; 2013 Sep 24; 6(9):932-42. PubMed ID: 24050860
    [Abstract] [Full Text] [Related]

  • 9. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
    Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, Han KH, Lee CW, Kang DH, Song JK, Kim JJ, Park SJ.
    J Am Coll Cardiol; 2005 Nov 15; 46(10):1833-7. PubMed ID: 16286167
    [Abstract] [Full Text] [Related]

  • 10. Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials.
    Sakurai R, Koo BK, Kaneda H, Bonneau HN, Nagai R.
    Int J Cardiol; 2013 Sep 01; 167(5):2250-8. PubMed ID: 22727963
    [Abstract] [Full Text] [Related]

  • 11. Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials).
    Lee SW, Ahn JM, Han S, Park GM, Cho YR, Lee WS, Jang JY, Kwon CH, Lee JY, Kim WJ, Kang SJ, Kim YH, Lee CW, Kim JJ, Park SW, Park SJ.
    Am J Cardiol; 2013 Nov 01; 112(9):1328-34. PubMed ID: 23890573
    [Abstract] [Full Text] [Related]

  • 12. Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: a meta-analysis.
    Chen Z, Qian J, Chen Y, Ma J, Ge J.
    J Clin Pharmacol; 2013 May 01; 53(5):532-9. PubMed ID: 23436428
    [Abstract] [Full Text] [Related]

  • 13. Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
    Geng DF, Liu M, Jin DM, Wu W, Deng J, Wang JF.
    Cardiology; 2012 May 01; 122(3):148-57. PubMed ID: 22832561
    [Abstract] [Full Text] [Related]

  • 14. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, Wang L, Kim EJ, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ, Korea Acute Myocardial Infarction Registry Investigators.
    Circulation; 2009 Jun 30; 119(25):3207-14. PubMed ID: 19528339
    [Abstract] [Full Text] [Related]

  • 15. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
    Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW.
    Circ Cardiovasc Interv; 2010 Feb 01; 3(1):17-26. PubMed ID: 20118150
    [Abstract] [Full Text] [Related]

  • 16. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
    Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Kim DK, Seol SH, Kim DI, Cho KI, Kim BH, Park YH, Je HG, Jeong YH, Kim WJ, Lee JY, Lee SW.
    Cardiology; 2012 Feb 01; 122(3):133-43. PubMed ID: 22832424
    [Abstract] [Full Text] [Related]

  • 17. Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    Zuliani Mauro MF, Mangione JA, Costa JR, Costa R, Piva E Mattos LA, Staico R, Feres F, Siqueira D, Sousa A, Abizaid A.
    J Invasive Cardiol; 2017 Mar 01; 29(3):76-81. PubMed ID: 28255102
    [Abstract] [Full Text] [Related]

  • 18. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL, SPIRIT III Investigators.
    Circulation; 2009 Feb 10; 119(5):680-6. PubMed ID: 19171853
    [Abstract] [Full Text] [Related]

  • 19. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis.
    Jennings DL, Kalus JS.
    J Clin Pharmacol; 2010 Apr 10; 50(4):415-21. PubMed ID: 20081227
    [Abstract] [Full Text] [Related]

  • 20. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Cassese S, De Luca G, Villari B, Berti S, Bellone P, Alfieri A, Montinaro A, Quaranta G, Marraccini P, Piscione F, MATRIX Study Investigators.
    Catheter Cardiovasc Interv; 2012 Sep 01; 80(3):408-16. PubMed ID: 21735531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.